Versartis Shares Outstanding 2013-2018 | VSAR

Current and historical number of shares outstanding for Versartis (VSAR) from 2013 to 2018. Diluted shares outstanding can be defined as the number of shares held by shareholders including insiders but not including a company's treasury shares assuming conversion of all convertible debt, securities, warrants and options.
Versartis Annual Shares Outstanding
(Millions of US $)
2017 $35
2016 $31
2015 $29
2014 $19
2013 $0
2012 $0
Versartis Quarterly Shares Outstanding
(Millions of US $)
Q2 2018 $36
Q1 2018 $36
Q4 2017 $35
Q3 2017 $36
Q2 2017 $35
Q1 2017 $35
Q4 2016 $31
Q3 2016 $30
Q2 2016 $29
Q1 2016 $29
Q4 2015 $29
Q3 2015 $29
Q2 2015 $29
Q1 2015 $28
Q4 2014 $19
Q3 2014 $24
Q2 2014 $24
Q1 2014 $3
Q4 2013 $0
Q3 2013 $0
Q2 2013 $0
Q1 2013 $0
Q4 2012 $0
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.063B $0.000B
Versartis, Inc. operates as a biotechnology company. It develops therapeutic proteins for the treatment of metabolic diseases and endocrine disorders. The Company is developing VRS-317, a long-acting recombinant human growth hormone, which is in Phase 2a clinical trials for the treatment of growth hormone deficiency. Versartis, Inc. is headquartered in Redwood City, California.
Stock Name Country Market Cap PE Ratio
Allergan (AGN) Ireland $62.458B 10.72
Teva Pharmaceutical Industries (TEVA) Israel $22.859B 6.39
Mylan (MYL) United Kingdom $19.184B 8.16
Bausch Health Cos (BHC) Canada $7.619B 5.69
Dr Reddy's Laboratories (RDY) India $5.346B 23.88
Mallinckrodt Public Limited Company (MNK) United Kingdom $2.588B 4.40
Supernus Pharmaceuticals (SUPN) United States $2.410B 25.78
Akorn (AKRX) United States $2.332B 11.55
Assembly Biosciences (ASMB) United States $1.006B 0.00
Amphastar Pharmaceuticals (AMPH) United States $0.801B 115.47
CymaBay Therapeutics (CBAY) United States $0.714B 0.00
Adamas Pharmaceuticals (ADMS) United States $0.628B 0.00
Progenics Pharmaceuticals (PGNX) United States $0.613B 0.00
Voyager Therapeutics (VYGR) United States $0.589B 0.00
Homology Medicines (FIXX) United States $0.582B 0.00
Corium (CORI) United States $0.314B 0.00
Teligent (TLGT) United States $0.220B 0.00
Sol-Gel Technologies (SLGL) Israel $0.124B 0.00
Zynerba Pharmaceuticals (ZYNE) United States $0.115B 0.00
Aquinox Pharmaceuticals (AQXP) Canada $0.073B 0.00
Aevi Genomic Medicine (GNMX) United States $0.058B 0.00
Evoke Pharma (EVOK) United States $0.043B 0.00
Pernix Therapeutics Holdings (PTX) United States $0.023B 0.00
Acasti Pharma (ACST) Canada $0.019B 0.00
China Pharma Holdings (CPHI) China $0.010B 0.00
Agile Therapeutics (AGRX) United States $0.009B 0.00